Contemporary real-world data for older Hodgkin lymphoma patient outcomes
| Citation . | Study type . | Population (study years) . | Study objectives . | Findings . |
|---|---|---|---|---|
| Moccia et al. 202035 | Retro | Ages ≥60, N = 269 (2000-2017) | 5-yr survival analyses and toxicity evaluation | BLT 17%; 5-yr PFS 53%, OS 64%, and CSS 86%; survival poorer ages >70 vs 60-70 yrs |
| Rodday et al. 202038 | SEER | Ages ≥65, N = 2825 (1999-2014) | Factors associated with first-line tx: full (25%), partial (36%), single-agent/RT (13%), no tx (26%) | Less-aggressive tx, frailty, heart disease, advanced stage, and treatment in Southern US associated with not receiving full chemotherapy |
| Kumar et al. 202130 | SEER | Ages ≥65, N = 1315 (2000-2013) | Prediction model of 1-yr mortality on standard chemotherapy | Final OS model: CCI, B-symptoms, advanced-stage disease, and older age |
| Orellana-Noia et al. 202128 | Retro | Age ≥60, N = 244 (2010-2018) | Predictors of survival based on GA and chemotherapy tx | BLT 18%; TRM 3.3%; inferior PFS and OS with ADL loss and with alternative tx vs conventional chemotherapy |
| Wahlin et al. 202117 | Registry | Age >60, N = 691 (2000-2014) | Survival by period, age, stage, sex, and ABVD vs CHOP | OS improved: 2010-2014 vs 2000-2009, with ABVD vs CHOP, and ages ≤70 vs >70 yrs |
| Rodday et al. 202137 | SEER | Ages ≥65, N = 2686 (2000-2013) | Survival by tx and stage with Cox regression, competing risk, and propensity | HL-specific survival for full tx vs partial tx (for advanced stage): HR 3.26 and “other cause” survival HR 1.76 |
| Overgaard et al. 202240 | Retro | Ages ≥60, N = 1554 (2000-2021) | Survival by stage and tx with multivariable analyses | 5-yr OS: AVD 64% vs ABVD 63% vs CHOP 46% (multivariable: AVD and ABVD > CHOP) |
| Cheng et al. 202215 | Registry | Ages ≥60, N = 744 (1961-2019); N = 401 (2000-2019) | 5-yr survival by decade and age with toxicity analyses | BLT 21%; survival improved by decade; post 2000: 5-yr PFS 60%, OS 65%, and DSS 76%; improved survival <70 vs ≥70 yrs |
| Shah et al. 202216 | SEER | Ages ≥60, N = 4957 (2006-2015) | Comparison 2006-2010 vs 2011-2015 and by race and clinical factors | Median OS by period 4 yr vs 4.8 yr, respectively; 5-year OS inferior among Hispanics |
| Goh et al. 202339 | Registry | Ages >60, N = 195 (2011-2020) | Survival analyses, including by treatment (with Cox regression) | TRM 5.2%; 2-yr PFS 64%, OS 71%; 2-yr PFS with anthracycline 70% vs 33% without; Cox OS model: CCI and anthracycline use |
| Citation . | Study type . | Population (study years) . | Study objectives . | Findings . |
|---|---|---|---|---|
| Moccia et al. 202035 | Retro | Ages ≥60, N = 269 (2000-2017) | 5-yr survival analyses and toxicity evaluation | BLT 17%; 5-yr PFS 53%, OS 64%, and CSS 86%; survival poorer ages >70 vs 60-70 yrs |
| Rodday et al. 202038 | SEER | Ages ≥65, N = 2825 (1999-2014) | Factors associated with first-line tx: full (25%), partial (36%), single-agent/RT (13%), no tx (26%) | Less-aggressive tx, frailty, heart disease, advanced stage, and treatment in Southern US associated with not receiving full chemotherapy |
| Kumar et al. 202130 | SEER | Ages ≥65, N = 1315 (2000-2013) | Prediction model of 1-yr mortality on standard chemotherapy | Final OS model: CCI, B-symptoms, advanced-stage disease, and older age |
| Orellana-Noia et al. 202128 | Retro | Age ≥60, N = 244 (2010-2018) | Predictors of survival based on GA and chemotherapy tx | BLT 18%; TRM 3.3%; inferior PFS and OS with ADL loss and with alternative tx vs conventional chemotherapy |
| Wahlin et al. 202117 | Registry | Age >60, N = 691 (2000-2014) | Survival by period, age, stage, sex, and ABVD vs CHOP | OS improved: 2010-2014 vs 2000-2009, with ABVD vs CHOP, and ages ≤70 vs >70 yrs |
| Rodday et al. 202137 | SEER | Ages ≥65, N = 2686 (2000-2013) | Survival by tx and stage with Cox regression, competing risk, and propensity | HL-specific survival for full tx vs partial tx (for advanced stage): HR 3.26 and “other cause” survival HR 1.76 |
| Overgaard et al. 202240 | Retro | Ages ≥60, N = 1554 (2000-2021) | Survival by stage and tx with multivariable analyses | 5-yr OS: AVD 64% vs ABVD 63% vs CHOP 46% (multivariable: AVD and ABVD > CHOP) |
| Cheng et al. 202215 | Registry | Ages ≥60, N = 744 (1961-2019); N = 401 (2000-2019) | 5-yr survival by decade and age with toxicity analyses | BLT 21%; survival improved by decade; post 2000: 5-yr PFS 60%, OS 65%, and DSS 76%; improved survival <70 vs ≥70 yrs |
| Shah et al. 202216 | SEER | Ages ≥60, N = 4957 (2006-2015) | Comparison 2006-2010 vs 2011-2015 and by race and clinical factors | Median OS by period 4 yr vs 4.8 yr, respectively; 5-year OS inferior among Hispanics |
| Goh et al. 202339 | Registry | Ages >60, N = 195 (2011-2020) | Survival analyses, including by treatment (with Cox regression) | TRM 5.2%; 2-yr PFS 64%, OS 71%; 2-yr PFS with anthracycline 70% vs 33% without; Cox OS model: CCI and anthracycline use |
ADL, activities of daily living; AVBD, doxorubicin, vinblastine, bleomycin, dacarbazine; AVD, doxorubicin, vinblastine, dacarbazine; BLT, bleomycin lung toxicity; CCI, Charlson Comorbidity Index; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CR, complete response; CSS, cause- specific survival; DSS, disease-specific survival; GA, geriatric assessments; HR, hazard ratio; N, number; OS, overall survival; PFS, progression-free survival; pts, patients; retro, retrospective; RT, radiation therapy; SEER, Surveillance, Epidemiology, and End Results registry; TRM, treatment-related mortality; tx, treatment; US, United States; yrs, years.